{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T10:20:13Z","timestamp":1756462813019,"version":"3.37.3"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100012659","name":"Foundation for Innovative Research Groups of the National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81872784","82151213"],"award-info":[{"award-number":["81872784","82151213"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.intimp.2024.112393","type":"journal-article","created":{"date-parts":[[2024,6,8]],"date-time":"2024-06-08T18:51:15Z","timestamp":1717872675000},"page":"112393","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["A PD-L1 tropism-expanded oncolytic adenovirus enhanced gene delivery efficiency and anti-tumor effects"],"prefix":"10.1016","volume":"137","author":[{"given":"Shengsheng","family":"Mei","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4427-7231","authenticated-orcid":false,"given":"Shanshan","family":"Peng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eu Gene","family":"Vong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4836-800X","authenticated-orcid":false,"given":"Jinbiao","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.intimp.2024.112393_b0005","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1089\/hum.2014.001","article-title":"Innate immunity to adenovirus","volume":"25","author":"Hendrickx","year":"2014","journal-title":"Hum. Gene Ther."},{"issue":"5","key":"10.1016\/j.intimp.2024.112393_b0010","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1111\/1759-7714.13043","article-title":"Updates to the antitumor mechanism of oncolytic virus","volume":"10","author":"Bai","year":"2019","journal-title":"Thorac Cancer."},{"issue":"1","key":"10.1016\/j.intimp.2024.112393_b0015","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/s41419-020-2236-3","article-title":"Characterization of virus-mediated immunogenic cancer cell death and the consequences for oncolytic virus-based immunotherapy of cancer","volume":"11","author":"Ma","year":"2020","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.intimp.2024.112393_b0020","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.copbio.2019.11.016","article-title":"Design and application of oncolytic viruses for cancer immunotherapy","volume":"65","author":"Yl\u00f6sm\u00e4ki","year":"2020","journal-title":"Curr. Opin. Biotechnol."},{"issue":"6","key":"10.1016\/j.intimp.2024.112393_b0025","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.cell.2017.08.027","article-title":"Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy","volume":"170","author":"Ribas","year":"2017","journal-title":"Cell"},{"issue":"11","key":"10.1016\/j.intimp.2024.112393_b0030","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1038\/sj.cgt.7701080","article-title":"A phase I trial of intravenous infusion of ONYX-015 and enbrel in solid tumor patients","volume":"14","author":"Nemunaitis","year":"2007","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.intimp.2024.112393_b0035","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1007\/978-1-59745-561-9_35","article-title":"Phase I clinical trial of locoregional administration of the oncolytic adenovirus ONYX-015 in combination with mitomycin-C, doxorubicin, and cisplatin chemotherapy in patients with advanced sarcomas","volume":"542","author":"Opyrchal","year":"2009","journal-title":"Methods Mol. Biol."},{"issue":"5304","key":"10.1016\/j.intimp.2024.112393_b0040","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1126\/science.275.5304.1320","article-title":"Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5","volume":"275","author":"Bergelson","year":"1997","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.intimp.2024.112393_b0045","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.ymthe.2005.05.008","article-title":"The influence of adenovirus fiber structure and function on vector development for gene therapy","volume":"12","author":"Nicklin","year":"2005","journal-title":"Mol. Ther."},{"issue":"24","key":"10.1016\/j.intimp.2024.112393_b0050","first-page":"5738","article-title":"Differential susceptibility of primary and established human glioma cells to adenovirus infection: targeting via the epidermal growth factor receptor achieves fiber receptor-independent gene transfer","volume":"58","author":"Miller","year":"1998","journal-title":"Cancer Res."},{"issue":"8","key":"10.1016\/j.intimp.2024.112393_b0055","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1001\/archotol.125.8.856","article-title":"Retargeting to EGFR enhances adenovirus infection efficiency of squamous cell carcinoma","volume":"125","author":"Blackwell","year":"1999","journal-title":"Arch. Otolaryngol. Head Neck Surg."},{"issue":"16","key":"10.1016\/j.intimp.2024.112393_b0060","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1089\/hum.1998.9.16-2363","article-title":"The presence of human coxsackievirus and adenovirus receptor is associated with efficient adenovirus-mediated transgene expression in human melanoma cell cultures","volume":"9","author":"Hemmi","year":"1998","journal-title":"Hum. Gene Ther."},{"issue":"2","key":"10.1016\/j.intimp.2024.112393_b0065","first-page":"325","article-title":"Loss of adenoviral receptor expression in human bladder cancer cells: a potential impact on the efficacy of gene therapy","volume":"59","author":"Li","year":"1999","journal-title":"Cancer Res."},{"issue":"12","key":"10.1016\/j.intimp.2024.112393_b0070","doi-asserted-by":"crossref","first-page":"9706","DOI":"10.1128\/JVI.72.12.9706-9713.1998","article-title":"An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism","volume":"72","author":"Dmitriev","year":"1998","journal-title":"J. Virol."},{"issue":"3","key":"10.1016\/j.intimp.2024.112393_b0075","first-page":"813","article-title":"Efficient oncolysis by a replicating adenovirus (ad) in vivo is critically dependent on tumor expression of primary ad receptors","volume":"61","author":"Douglas","year":"2001","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.intimp.2024.112393_b0080","doi-asserted-by":"crossref","first-page":"45","DOI":"10.3109\/08830185.2013.823420","article-title":"Adenoviruses types, cell receptors and local innate cytokines in adenovirus infection","volume":"33","author":"Chen","year":"2014","journal-title":"Int. Rev. Immunol."},{"issue":"19","key":"10.1016\/j.intimp.2024.112393_b0085","doi-asserted-by":"crossref","first-page":"5713","DOI":"10.7150\/jca.46463","article-title":"A tropism-transformed oncolytic adenovirus with dual capsid modifications for enhanced glioblastoma therapy","volume":"11","author":"Wang","year":"2020","journal-title":"J. Cancer"},{"issue":"2","key":"10.1016\/j.intimp.2024.112393_b0090","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1006\/gyno.1999.5432","article-title":"An advanced generation of adenoviral vectors selectively enhances gene transfer for ovarian cancer gene therapy approaches","volume":"74","author":"Vanderkwaak","year":"1999","journal-title":"Gynecol. Oncol."},{"issue":"10","key":"10.1016\/j.intimp.2024.112393_b0095","doi-asserted-by":"crossref","first-page":"2728","DOI":"10.1158\/1535-7163.MCT-07-0176","article-title":"Treatment of metastatic renal cancer with capsid-modified oncolytic adenoviruses","volume":"6","author":"Guse","year":"2007","journal-title":"Mol. Cancer Ther."},{"issue":"11","key":"10.1016\/j.intimp.2024.112393_b0100","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1002\/jgm.1385","article-title":"A chimeric adenovirus with an Ad 3 fiber knob modification augments glioma virotherapy","volume":"11","author":"Nandi","year":"2009","journal-title":"J. Gene Med."},{"issue":"18","key":"10.1016\/j.intimp.2024.112393_b0105","doi-asserted-by":"crossref","first-page":"8783","DOI":"10.1158\/0008-5472.CAN-07-0357","article-title":"A capsid-modified, conditionally replicating oncolytic adenovirus vector expressing TRAIL Leads to enhanced cancer cell killing in human glioblastoma models","volume":"67","author":"Wohlfahrt","year":"2007","journal-title":"Cancer Res."},{"issue":"11","key":"10.1016\/j.intimp.2024.112393_b0110","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1080\/15384047.2017.1395115","article-title":"A novel fiber chimeric conditionally replicative adenovirus-Ad5\/F35 for tumor therapy","volume":"18","author":"Yang","year":"2017","journal-title":"Cancer Biol. Ther."},{"issue":"17","key":"10.1016\/j.intimp.2024.112393_b0115","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1089\/104303403322542284","article-title":"dl-VSVG-LacZ, a vesicular stomatitis virus glycoprotein epitope-incorporated adenovirus, exhibits marked enhancement in gene transduction efficiency","volume":"14","author":"Yun","year":"2003","journal-title":"Hum. Gene Ther."},{"issue":"11","key":"10.1016\/j.intimp.2024.112393_b0120","doi-asserted-by":"crossref","first-page":"8221","DOI":"10.1128\/jvi.71.11.8221-8229.1997","article-title":"Increased in vitro and in vivo gene transfer by adenovirus vectors containing chimeric fiber proteins","volume":"71","author":"Wickham","year":"1997","journal-title":"J. Virol."},{"issue":"4","key":"10.1016\/j.intimp.2024.112393_b0125","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1172\/JCI5309","article-title":"CAR-dependent and CAR-independent pathways of adenovirus vector-mediated gene transfer and expression in human fibroblasts","volume":"103","author":"Hidaka","year":"1999","journal-title":"J. Clin. Invest."},{"issue":"12","key":"10.1016\/j.intimp.2024.112393_b0130","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1016\/j.str.2015.09.010","article-title":"Structure of the complex of human programmed death 1, PD-1, and its ligand PD-L1","volume":"23","author":"Zak","year":"2015","journal-title":"Structure"},{"issue":"128","key":"10.1016\/j.intimp.2024.112393_b0135","article-title":"A dual-functional oncolytic adenovirus ZD55-aPD-L1 scFv armed with PD-L1 inhibitor potentiates its antitumor activity","volume":"15","author":"Mei","year":"2024","journal-title":"Int. Immunopharmacol."},{"issue":"9","key":"10.1016\/j.intimp.2024.112393_b0140","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1038\/sj.cgt.7700928","article-title":"Transductional targeting of adenovirus vectors for gene therapy","volume":"13","author":"Glasgow","year":"2006","journal-title":"Cancer Gene Ther."},{"issue":"10","key":"10.1016\/j.intimp.2024.112393_b0145","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1089\/hum.2009.038","article-title":"Replacement of adenovirus type 5 fiber shaft heparan sulfate proteoglycan-binding domain with RGD for improved tumor infectivity and targeting","volume":"20","author":"Bayo-Puxan","year":"2009","journal-title":"Hum. Gene Ther."},{"issue":"13","key":"10.1016\/j.intimp.2024.112393_b0150","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1038\/gt.2008.26","article-title":"Adenovirus targeting to HLA-A1\/MAGE-A1-positive tumor cells by fusing a single-chain T-cell receptor with minor capsid protein IX","volume":"15","author":"de Vrij","year":"2008","journal-title":"Gene Ther."},{"issue":"2","key":"10.1016\/j.intimp.2024.112393_b0155","doi-asserted-by":"crossref","first-page":"151","DOI":"10.3109\/07853890.2010.538079","article-title":"In vivo and in vitro distribution of type 5 and fiber-modified oncolytic adenoviruses in human blood compartments","volume":"43","author":"Escutenaire","year":"2011","journal-title":"Ann. Med."},{"issue":"1","key":"10.1016\/j.intimp.2024.112393_b0160","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1038\/s41467-017-00799-8","article-title":"PD-L1 is an activation-independent marker of brown adipocytes","volume":"8","author":"Ingram","year":"2017","journal-title":"Nat. Commun."},{"issue":"3","key":"10.1016\/j.intimp.2024.112393_b0165","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1097\/CJI.0b013e31802e085a","article-title":"The new B7s: playing a pivotal role in tumor immunity","volume":"30","author":"Flies","year":"2007","journal-title":"J. Immunother."},{"key":"10.1016\/j.intimp.2024.112393_b0170","doi-asserted-by":"crossref","unstructured":"Magiera-Mularz K, Kocik J, Musielak B, Plewka J, Sala D, Machula M, Grudnik P, Hajduk M, Czepiel M, Siedlar M, Holak TA, Skalniak L. Human and mouse PD-L1: similar molecular structure, but different druggability profiles. iScience. 2020 24(1):101960.","DOI":"10.1016\/j.isci.2020.101960"},{"issue":"10304","key":"10.1016\/j.intimp.2024.112393_b0175","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/S0140-6736(21)01206-X","article-title":"Immune checkpoint inhibitors in melanoma","volume":"398","author":"Carlino","year":"2021","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.intimp.2024.112393_b0180","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1016\/j.cell.2023.03.006","article-title":"Immune checkpoint therapy-current perspectives and future directions","volume":"186","author":"Sharma","year":"2023","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.intimp.2024.112393_b0185","doi-asserted-by":"crossref","first-page":"e000450","DOI":"10.1136\/jitc-2019-000450","article-title":"PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations","volume":"8","author":"Fabian","year":"2020","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.intimp.2024.112393_b0190","doi-asserted-by":"crossref","first-page":"e002500","DOI":"10.1136\/jitc-2021-002500","article-title":"PD-L1 CAR effector cells induce self-amplifying cytotoxic effects against target cells","volume":"10","author":"Bajor","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.intimp.2024.112393_b0195","article-title":"Peptide-functionalized, -assembled and -loaded nanoparticles in cancer therapy","volume":"16","author":"Dai","year":"2024","journal-title":"Drug Discov. Today"},{"issue":"45","key":"10.1016\/j.intimp.2024.112393_b0200","doi-asserted-by":"crossref","first-page":"13627","DOI":"10.1021\/acs.langmuir.2c02197","article-title":"Designed peptide assemblies for efficient gene delivery","volume":"38","author":"Ma","year":"2022","journal-title":"Langmuir"},{"issue":"3","key":"10.1016\/j.intimp.2024.112393_b0205","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1021\/acs.jmedchem.3c01835","article-title":"Peptide-drug conjugates: an emerging direction for the next generation of peptide therapeutics","volume":"67","author":"Dean","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.intimp.2024.112393_b0210","doi-asserted-by":"crossref","unstructured":"Kour A, Panda HS, Singh IR, Kumar A, Panda JJ. Peptide-metal nanohybrids (PMN): PromisinKour A, Panda HS, Singh IR, Kumar A, Panda JJ. Peptide-metal nanohybrids (PMN): Promising entities for combating neurological maladies. Adv Colloid Interface Sci. 2023 Aug;318:102954.","DOI":"10.1016\/j.cis.2023.102954"}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576924009135?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576924009135?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,4]],"date-time":"2024-10-04T17:30:35Z","timestamp":1728063035000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576924009135"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":42,"alternative-id":["S1567576924009135"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2024.112393","relation":{},"ISSN":["1567-5769"],"issn-type":[{"type":"print","value":"1567-5769"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A PD-L1 tropism-expanded oncolytic adenovirus enhanced gene delivery efficiency and anti-tumor effects","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2024.112393","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"112393"}}